Navigation Links
NIAID to advance B-cell approach to HIV vaccines
Date:5/20/2008

To advance underdeveloped approaches to designing a preventive HIV vaccine, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is launching a new program to foster the study of B cells, immune cells that can produce antibodies with the capacity to neutralize HIV. The $15.6 million, five-year program will strengthen and expand the scientific foundation of HIV vaccine research through a network of 10 research teams nationwide that will share resources, methods and data to accelerate progress.

In the immune system, B cells recognize key parts of microbes, called antigens. Then, in cooperation with T cellsparts of the immune system that kill cells infected by pathogensa reaction is triggered that leads B cells to produce antibodies, which can lock onto antigens and sweep them out of the body. HIV is devilishly good at fooling B cells and shielding itself from antibodies or changing its antigenic parts, so antibodies can rarely rid the body of the virus.

The new NIAID research program aims to uncover mechanisms that will enable scientists to outwit HIV and stimulate the B-cell production of long-lasting antibodies that can neutralize many strains of the virus; such antibodies are known as broadly neutralizing.

This program reflects our commitment to probe the fundamental science underlying HIV vaccine development, says NIAID Director Anthony S. Fauci, M.D. The study of B cells and broadly neutralizing antibodies to HIV will answer pressing, basic scientific questions and bring greater balance to our portfolio of HIV vaccine discovery research.

In recent years, investigator-initiated grants supported by NIAID have focused more heavily on T-cell based approaches to preventive HIV vaccines than on B-cell based ones. Many experts believe a successful HIV vaccine will probably need to activate both T cells and B cells; consequently, NIAIDs creation of the new B-cell research program is an important stimulus for HIV vaccine discovery.

Some evidence suggests that the programs goal of eliciting broadly neutralizing antibodies to HIV, although extremely difficult, may be feasible. Scientists have discovered that some HIV-infected individuals naturally but rarely produce broadly neutralizing antibodies to HIV. Giving such antibodies experimentally to monkeys protected the animals from HIV infection after exposure to the virus. Scientists now face the challenge of how to stimulate the human immune system to predictably produce broadly neutralizing antibodies to HIV through vaccination.

Combining experience with innovation, NIAID is awarding the B-cell program grants to four investigators who already have established a body of research on B cells and antibodies in the context of HIV, and to six investigators with less experience in this area who have exceptionally creative ideas. Each grantees combined expertise in basic immunology and HIV pathogenesis reflects the programs roots in a collaboration between NIAIDs Division of AIDS and its Division of Allergy, Immunology and Transplantation. The joint awards by the two NIAID divisions culminate a 20-month planning and implementation process that began in September 2006. Scientific discussions a year and a half later, during the NIAID HIV Vaccine Summit in March 2008, underscored the importance of broadly neutralizing antibodies as a promising approach that merits further investigation.

The grants are being awarded to the scientists as follows:

Dennis R. Burton, Ph.D.
The Scripps Research Institute

James E. Crowe, Jr., M.D.
Vanderbilt University School of Medicine

Donald N. Forthal, M.D.
University of California, Irvine

Maureen M. Goodenow, Ph.D.
University of Florida College of Medicine

Min Lu, Ph.D.
Weill Cornell Medical College

Abraham Pinter, Ph.D.
University of Medicine and Dentistry of New Jersey

Gerald V. Quinnan Jr., M.D.
Uniformed Services University of the Health Sciences

Ignacio Sanz, M.D.
University of Rochester School of Medicine and Dentistry

Harry W. Schroeder, Jr., M.D., Ph.D.
The University of Alabama at Birmingham

Raul M. Torres, Ph.D.
University of Colorado at Denver and Health Sciences Center


'/>"/>

Contact: Laura Sivitz
sivitzl@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID describes research priorities to fight drug-resistant tuberculosis
2. NIAID to convene HIV Vaccine Summit
3. NIAID scientists identify new cellular receptor for HIV
4. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
5. NIAID funds $51M contract to create comprehensive model of immune responses
6. Advances Aid Treatment, Diagnosis of Celiac Disease
7. 2008 American Academy of Pediatric Dentistry Annual Session Highlights Emerging Scientific Advancements
8. Partnerships Effective Communicators of Cancer Advances
9. Partnership of academic centers and community hospitals effective model for disseminating advances
10. THE Aesthetic Show Advances $34 Billion Market
11. Singulex Advances Conversation on Personalized Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: